Sagimet Biosciences Inc Series A (SGMT) Stock Price, Quote & News

Company Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 561 8600

Website: www.sagimet.com

Address:

155 Bovet Road, Suite 303, San Mateo, United States

Biostock Jan. 13 at 7:00 PM

$SGMT MASH and ACNE TAM in Billions. $SPY $QQQ

0 · Reply

Bondra Jan. 13 at 5:34 PM

$CDXS $SGMT The true heroes of my portfolio. Green.

0 · Reply

Biostock Jan. 12 at 6:25 AM

$SGMT MASH and ACNE should value at 27+

0 · Reply

Jaybird99 Jan. 11 at 12:47 AM

$SGMT keyword "exceeding expectations" The poster highlighted denifanstat's anti-fibrotic effects and its potential in MASH, a severe liver disease, with results exceeding expectations and boosting confidence in their FASN inhibitor approach

0 · Reply

JCharmin Jan. 10 at 11:08 PM

$SGMT

0 · Reply

Dark_Horse_Investments Jan. 9 at 6:26 PM

$SGMT good move today. Triple weekly volume, 13% up! what is driving interest?

3 · Reply

Wolly99 Jan. 9 at 5:31 PM

$ALT I was invested in $SGMT last year and did 2x with it - very happy obviously. I sold bc they abandoned p3 bc they didn't have the funding and there is no weight loss. But I think FASN inhibitors are interesting and SGMT could be a target for takeover. I don't love that they're combining resmetiron+FASN by going back to p1 bc I think MDGL will sue them....but one to keep on the radar

5 · Reply

BearKilllaAlerts Jan. 9 at 5:02 PM

$SGMT 🚨 BULLISH ON $SGMT! 🚀 BearKillaAlerts flagged this one with strong momentum and solid technicals. Not tracking premium alerts? Subscribe to BearKillaAlerts for real-time scans and winning setups like this. 👉 Subscribe to BearKillaAlerts now #SGMT #Biotech #Momentum

1 · Reply

BioRich Jan. 9 at 4:09 PM

$ALT Looks like $SGMT is presenting at MASH-TAG tomorrow. I think they should be on this list as well. $IVA, $SGMT and $VKTX should be on this list. I don't believe, with $ALT's miserable Fibrosis Failure, should be on this list. (Note - $ALT FAILED their Fibrosis Improvement Endpoint with the most reliable and effective method approved. PathAI was an AdHoc use for metrics that don't correlate directly to what $ALT failed...something that many continue to miss). Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we learn and find these gems (SGMT, IVA, VKTX...not ALT). Let's make some (more) money. Cheers!

1 · Reply

DonkeyPuncherDude Jan. 9 at 3:56 PM

$SGMT Giddy up! Nice volume.

0 · Reply

Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference

Dec 19, 2025, 2:42 PM EST - 26 days ago

Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market

Dec 18, 2025, 7:00 AM EST - 27 days ago

Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination

Dec 10, 2025, 7:03 AM EST - 5 weeks ago

Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration

Dec 10, 2025, 4:15 AM EST - 5 weeks ago

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment

Dec 9, 2025, 4:05 PM EST - 5 weeks ago

Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 20, 2025, 7:00 AM EST - 7 weeks ago

Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference

Nov 18, 2025, 5:48 AM EST - 2 months ago

Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts

Nov 10, 2025, 7:00 AM EST - 2 months ago

Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025

Oct 24, 2025, 7:00 AM EDT - 2 months ago

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

Oct 14, 2025, 7:00 AM EDT - 3 months ago

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

Oct 14, 2025, 6:00 AM EDT - 3 months ago

Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

Oct 7, 2025, 9:30 AM EDT - 3 months ago

Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts

Oct 7, 2025, 7:00 AM EDT - 3 months ago

Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025

Sep 17, 2025, 7:00 AM EDT - 4 months ago

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

Sep 10, 2025, 7:00 AM EDT - 4 months ago

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

Sep 7, 2025, 10:05 PM EDT - 4 months ago

Sagimet Biosciences Inc. (SGMT) Presents At Cantor Global Healthcare Conference 2025 Transcript

Aug 29, 2025, 11:19 AM EDT - 4 months ago

Sagimet Gains Momentum As FDA Eases Path For MASH Drug Development

Aug 26, 2025, 7:00 AM EDT - 5 months ago

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Aug 13, 2025, 7:30 AM EDT - 5 months ago

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 5, 2025, 7:00 AM EDT - 5 months ago

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jun 9, 2025, 7:00 AM EDT - 7 months ago

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

Jun 4, 2025, 1:45 PM EDT - 8 months ago

Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567

Jun 4, 2025, 5:00 AM EDT - 8 months ago

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

May 22, 2025, 8:00 AM EDT - 8 months ago

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

May 8, 2025, 6:00 AM EDT - 8 months ago

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Mar 12, 2025, 7:30 AM EDT - 11 months ago

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Mar 11, 2025, 8:00 AM EDT - 11 months ago

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

Mar 7, 2025, 4:27 PM EST - 11 months ago

Sagimet Biosciences' Denifanstat Should Be Worth More Today

Nov 14, 2024, 3:56 PM EST - 1 year ago

Sagimet: More Than Just A MASH Drug Development Biotech

Nov 12, 2024, 6:30 AM EST - 1 year ago

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Oct 18, 2024, 3:10 PM EDT - 1 year ago

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat

Oct 11, 2024, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Oct 1, 2024, 7:00 AM EDT - 1 year ago

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

Oct 1, 2024, 12:05 AM EDT - 1 year ago

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 12, 2024, 7:30 AM EDT - 1 year ago

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Jul 31, 2024, 12:24 PM EDT - 1 year ago

Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Jun 6, 2024, 5:00 AM EDT - 1 year ago

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

May 16, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

May 15, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 7, 2024, 8:00 AM EDT - 1 year ago

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

May 6, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

Apr 26, 2024, 12:23 PM EDT - 1 year ago

Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

Mar 25, 2024, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Mar 25, 2024, 6:15 AM EDT - 1 year ago

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Jan 25, 2024, 8:58 PM EST - 2 years ago

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

Biostock Jan. 13 at 7:00 PM

$SGMT MASH and ACNE TAM in Billions. $SPY $QQQ

0 · Reply

Bondra Jan. 13 at 5:34 PM

$CDXS $SGMT The true heroes of my portfolio. Green.

0 · Reply

Biostock Jan. 12 at 6:25 AM

$SGMT MASH and ACNE should value at 27+

0 · Reply

Jaybird99 Jan. 11 at 12:47 AM

0 · Reply

JCharmin Jan. 10 at 11:08 PM

$SGMT

0 · Reply

Dark_Horse_Investments Jan. 9 at 6:26 PM

$SGMT good move today. Triple weekly volume, 13% up! what is driving interest?

3 · Reply

Wolly99 Jan. 9 at 5:31 PM

5 · Reply

BearKilllaAlerts Jan. 9 at 5:02 PM

1 · Reply

BioRich Jan. 9 at 4:09 PM

1 · Reply

DonkeyPuncherDude Jan. 9 at 3:56 PM

$SGMT Giddy up! Nice volume.

0 · Reply

Geohotventures Jan. 9 at 3:19 PM

$SGMT Good to see!

0 · Reply

buymoremakemore Jan. 9 at 2:46 PM

$SGMT ok well I got my 10k shares. 12k wouldve been nice but ill hold these 30k shares strong

0 · Reply

nastento Jan. 9 at 2:37 PM

$SGMT interesting move

0 · Reply

Whiskeyunderthebed Jan. 9 at 2:21 PM

$SGMT https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-expands-its-mash-pipeline-exclusive-global-license

2 · Reply

Smellmahass Jan. 9 at 2:09 PM

$SGMT They presentind data tomorrow? Is this a stock mover?

0 · Reply

Whiskeyunderthebed Jan. 9 at 1:27 PM

$SGMT The author of the poster presented yesterday was from Rohit Loomba, M.D.-previously worked at 89Bio previously: anti-fibrotic effects in F3 and qFibrosis stage 4 MASH patients.

0 · Reply

buymoremakemore Jan. 9 at 1:10 PM

$SGMT A paid research service I use re-recommended SGMT yesterday after hours. Not saying that is why price has been good after hours but jeez hopefully I can get in at a good price this morning when market opens. My entries usually get botched when they recommend a stock

4 · Reply

Mikrus36 Jan. 9 at 12:04 PM

$SGMT low vol

0 · Reply

DonkeyPuncherDude Jan. 9 at 12:02 PM

$SGMT Currently up 10% PM. What’s going on? Hmm

0 · Reply

buymoremakemore Jan. 9 at 1:58 AM

$SGMT Buying 10k to 12k more shares tomorrow. Hoping to get in below $6. Then we moon!

0 · Reply

nastento Jan. 8 at 10:08 PM

$SGMT only 71k shares traded

0 · Reply

Ron_Burn Jan. 8 at 10:00 PM

$SGMT has potential.

0 · Reply

Market Cap	201.96M
Revenue (ttm)	0.00
Net Income (ttm)	-45.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	697,600
Avg Vol	571,418
Day's Range	N/A - N/A
Shares Out	32.52M
Stochastic %K	78%
Beta	3.39
Analysts	Strong Sell
Price Target	$28.25